Investigation into Hims & Hers Health, Inc. Over Securities Laws Violations

Strategic Insights

Jul 13, 2025 — 1 min read

Faruqi & Faruqi, LLP, a leading national securities law firm, has launched an investigation into potential claims against Hims & Hers Health, Inc. (NYSE: HIMS) due to allegedly false and misleading statements and failure to disclose material information. The firm reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the Company. The complaint alleges that Hims' executives violated federal securities laws by making false statements about the Company's business, operations, and prospects, particularly regarding its collaboration with Novo Nordisk.

Key Takeaways:

The lawsuit alleges that Hims & Hers Health, Inc. engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(r) that put patient safety at risk."
The Company's executives allegedly made false and/or misleading statements about the Company's business, operations, and prospects, particularly regarding its partnership with Novo Nordisk.
On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims due to non-compliance with the law and concerns over patient safety.
Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, following the announcement.
Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or choose to do nothing and remain an absent class member.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class.

Statistics:

$22.24: the amount by which Hims' stock price fell on June 23, 2025
34.6%: the percentage stock price decrease on June 23, 2025
$41.98: the closing price of Hims' stock on June 23, 2025
August 25, 2025: the deadline to seek the role of lead plaintiff

Sources:

"Faruqi & Faruqi, LLP Announces Investigation of Hims & Hers Health, Inc. (NYSE: HIMS) and Related Securities Class Action Lawsuit - HIMS"
www.faruqilaw.com

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients